• Earlier in January 2026, Ascendis Pharma A/S reported positive Week 52 topline Phase 2 COACH trial results for its once-weekly TransCon CNP and TransCon hGH combination in children with achondroplasia, alongside amending its Articles of Association to allow for new warrant grants.
• The COACH data highlighted durable growth, improved body proportionality, and a safety profile consistent with monotherapies, reinforcing TransCon CNP’s potential backbone role in treating achondroplasia as regulators review it under Priority Review in the US and Europe.
• With encouraging COACH trial outcomes and the Priority Review for TransCon CNP now in focus, we’ll explore how this shapes Ascendis Pharma’s investment narrative.

Uncover the next big…